Develops antibody therapeutics for hair loss and endometriosis.
Jun 2026Revenue $1.56M/yrExpenses $128M/yr
No trendCash runway ≈ 1.8 years from Jun 2026
Figures by year
When will Absci be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $1.56M and expenses $128M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $2.80M | $123M | −$120M |
| Dec 2024 | $4.53M | $113M | −$109M |
| Dec 2023 | $5.72M | $121M | −$116M |
| Dec 2022 | $4.53M | $111M | −$107M |
| Dec 2021 | $4.01M | $79.2M | −$75.2M |
| Dec 2020 | $4.12M | $17.4M | −$13.3M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.